Keywords
Hemocromatosis
Desensibilización
Abstract
Abstract
Background: Deferasirox is an active iron chelator, used in the treatment of iron overload such as hemochromatosis. Up to 28% may present adverse reactions to said drug. A desensitization protocol for this drug may be useful when there are no other therapeutic options.
Case report: A 52-year-old female with a diagnosis of hemochromatosis who began treatment with phlebotomy, poor response and tolerance, so it was decided to treat with deferasirox 500 mg daily, presenting symptoms of urticaria and angioedema on the third dose. Hospitalization was decided for a desensitization protocol with an initial dose of 0.6mg with a gradual increase in the dose, reaching a maintenance dose of 500 mg per day on the third day.
Conclusion: The rapid desensitization protocol for Deferasirox is useful when there is no response or therapeutic alternative.
References
Exjade (deferasirox) [información de prescripción]. East Hanover, Nueva Jersey: Novartis Pharmaceuticals Corporation; julio de 2020
Jadenu (deferasirox) [información de prescripción]. East Hanover, Nueva Jersey: Novartis Pharmaceuticals Corporation; julio de 2020.
Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU, Porto G. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood. 2022;139(20):3018-3029. doi:10.1182/blood.2021011338
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502. doi:10.1016/j.jhep.2022.03.033
Alvarenga AM, Brissot P, Santos PCJL. Haemochromatosis revisited. World J Hepatol. 2022;14(11):1931-1939. doi:10.4254/wjh.v14.i11.1931
Olynyk JK, Ramm GA. Hemochromatosis. N Engl J Med. 2022;387(23):2159-2170. doi:10.1056/NEJMra2119758
Bruner KE, White KM. Deferasirox desensitization. J Allergy Clin Immunol Pract. 2016;4(1):171-172. doi:10.1016/j.jaip.2015.09.007
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2023 Revista Alergia México